Initial vancomycin versus metronidazole for the treatment of

first-episode non-severe Clostridioides difficile infection

1

2

1

3	
4	Kevin Zhang MD(c), <sup>1,*</sup> Patricia Beckett RN, <sup>2</sup> Salaheddin Abouanaser MD, <sup>2</sup> Marek
5 6	Smieja MD, PhD <sup>2,3</sup>
7	<sup>1</sup> Faculty of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada
8	<sup>2</sup> St. Joseph's Healthcare Hamilton, Hamilton, Ontario, L8N 4A6, Canada
9 10	<sup>3</sup> Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, L8S 4L8, Canada
11	
12	*Corresponding author: kevink.zhang@mail.utoronto.ca
13	
14	Email Addresses
15	KZ: kevink.zhang@mail.utoronto.ca
16	PB: pbeckett@stjosham.on.ca
17	SA: salaheddin.abouanaser@medportal.ca
18	MS: smiejam@mcmaster.ca
19	
20	Correspondence
21	Kevin Zhang
22	Faculty of Medicine, University of Toronto
23	1 King's College Circle
24	Toronto, ON M5S 1A8
25	kevink.zhang@mail.utoronto.ca, (+1)416-978-6585
26	
27	Keywords: Clostridioides difficile; Clostridium difficile; vancomycin; metronidazole;
28	recurrence; incidence; mortality
29	
30	
31	

#### NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 2

### 32 Abstract

Background: *Clostridioides difficile* infection (CDI) is an important cause of nosocomial diarrhea. Given the discrepancy in current treatment guidelines for mild CDI, we sought

to evaluate the use of initial vancomycin versus metronidazole for the treatment of first-

36 episode non-severe infection.

37 Methods: We conducted a retrospective cohort study of all adult inpatients with first-

episode CDI at our institution from January 2013 to May 2018. CDI was defined as a

39 positive Clostridioides difficile loop-mediated isothermal amplification assay, in

40 conjunction with ≥3 type 5–7 stools on the Bristol stool scale. To evaluate the impact of

initial vancomycin treatment on adverse clinical outcomes in patients with first-episode

non-severe CDI, the initial vancomycin versus initial metronidazole cohorts were first

examined in an unadjusted logistic regression analysis for any combination of

recurrence, incident infection, and all-cause 30-day mortality, followed by an adjusted

45 multivariable analysis.

46 **Results:** A total of 737 cases were included. Patients had a median age of 72.3 years

47 (Q1: 61.2, Q3: 83.3) and 628 (85.2%) were classified as non-severe CDI. Among

48 patients with non-severe CDI (n = 628), recurrence, incident infection, and 30-day

49 mortality rates were 15.1%, 7.7%, and 13.1%, respectively, when treated with initial

50 metronidazole, compared to 16.9%, 4.2%, and 11.4%, respectively, when treated with

51 initial vancomycin. In an adjusted multivariable analysis, the use of initial vancomycin for

52 the treatment of non-severe CDI was associated with a reduction in incident infection

53 (OR<sub>adj</sub>: 0.18; 95% CI: 0.04–0.75; P=0.019) and the composite outcome of incident

<sup>54</sup> infection or 30-day mortality (OR<sub>adj</sub>: 0.42; 95% CI: 0.22–0.79; P=0.007), compared to

55 initial metronidazole.

56 **Conclusions:** Initial vancomycin was associated with a reduced rate of incident

57 infection and the composite outcome of incident infection or all-cause 30-day mortality

in the treatment of adult inpatients with first-episode non-severe CDI, compared to initial

59 metronidazole. Our findings support the use of initial vancomycin for all inpatients with

60 CDI, irrespective of disease severity, as recommended by Infectious Diseases Society

of America guidelines.

62

Keywords: Clostridioides difficile; Clostridium difficile; vancomycin; metronidazole;
 recurrence; incidence; mortality

65

#### 3

# 67 Background

Clostridioides difficile infection (CDI) manifests itself in patients with an altered gut 68 69 microbiota, and is commonly caused by exposure to antibiotics [1]. As the leading cause of nosocomial diarrhea, CDI continues to be a major burden within healthcare 70 71 institutions and in the community [1]. Patients with CDI suffer from copious amounts of 72 uncontrolled diarrhea, leading to a higher risk of life-threatening colitis and a lower guality of life. Despite undergoing lengthy courses of antimicrobial therapy, however, 73 recurrence is common, with approximately 20% of patients experiencing debilitating 74 episodes of repeated disease [2]. Recurrent CDI is associated with a greater risk for 75

- future recurrence and severe complications such as hypotension, perforation, and toxic
- 77 megacolon [2]. Therefore, early interventions aimed at preventing recurrent CDI and
- reinfection are needed to improve outcomes, decrease the number of patient days
- spent in isolation, and improve quality of life.

80 St. Joseph's Healthcare Hamilton is a multi-site teaching hospital located in Hamilton,

- 81 Ontario, Canada with a dedicated *Clostridioides difficile* consultation service for
- inpatients and referred outpatients. While the consultation team may offer fecal
- 83 microbiota transplantation to patients with multiple CDI episodes or refractory disease
- [3, 4], clinical interventions for first-episode CDI primarily involve the use of antibiotics.
- In the past, metronidazole was indicated for non-severe CDI at our institution, while
- vancomycin was reserved for febrile patients with elevated white counts or for recurrent
- episodes. In recent years, however, there has been a shift to initial vancomycin to treat
- first-episode non-severe CDI at our institution, which is consistent with recent guidelines
- <sup>89</sup> published by the Infectious Diseases Society of America (IDSA) [5]. Importantly,
- guidelines published by the European Society of Clinical Microbiology and Infectious
   Diseases, the World Society of Emergency Surgery, and the Australasian Society of
- 92 Infectious Diseases still recommend the use of metronidazole for the first episode of
- 93 non-severe disease [6–8].

94 Although initial vancomycin treatment is recommended by most guidelines to treat

- 95 severe CDI, there exists a discrepancy in treatment recommendations for first-episode
- non-severe CDI [5–8]. There have been limited studies with long-term follow-up
- 97 evaluating the use of initial vancomycin compared to initial metronidazole to treat non-
- 98 severe inpatient CDI. In two large randomized controlled trials with follow-up of 3 weeks
- <sup>99</sup> and 4 weeks, respectively, subgroup analyses stratified by severity did not demonstrate
- significant differences in relapse rates between the vancomycin and metronidazole
- treatment groups for non-severe CDI [9, 10]. Similarly, two cohort studies reported that
- relapse rates and 30-day mortality did not differ among patients with mild-to-moderate
- 103 CDI treated with metronidazole or vancomycin [11, 12]. Therefore, we sought to identify
- 104 predictors of adverse clinical outcomes and evaluate the use of initial vancomycin

4

versus metronidazole for the treatment of first-episode non-severe CDI among adultinpatients.

### 107 Methods

108 We conducted a retrospective cohort study of all adult inpatients with first-episode CDI at our institution from January 1, 2013 to May 31, 2018. Patients were identified from 109 hospital infection control registries maintained by Infection Prevention and Control, and 110 all entries were validated against data reported to the Ontario Ministry of Health and 111 Long-Term Care. A CDI episode was characterized clinically as 3 or more type 5-7 112 113 diarrheal stools on the Bristol stool scale, together with a positive Clostridioides difficile toxin gene loop-mediated isothermal amplification assay, in accordance with IDSA 114 guidelines [5]. Patients with a prior history of CDI were excluded from the study. 115 Similarly, colonized patients who had a positive toxin assay but did not meet the clinical 116 117 criteria of 3 or more type 5-7 loose stools were excluded. Data abstracted included: demographics, specimen collection date, date of symptom onset, source of acquisition, 118 unit in which CDI was first diagnosed (medical, surgical, or nephrology), clinical 119 indicators at the time of diagnosis, CDI treatment, number of isolation days, and 120 outcomes including: recurrence, incident infection, and death. Time to treatment and 121 122 time to recurrence were measured from the start of the initial CDI diagnosis. Hospitalacquired infection (HAI) was defined as CDI present >72 hours after admission or 123

infection present on admission, whereas non-HAI was defined as CDI present ≤72

hours after admission [13].

126 The primary exposures in this study were the treatment of first-episode non-severe CDI

127 with initial vancomycin or metronidazole. The outcomes of interest were recurrence,

- incident infection, and all-cause 30-day mortality. All patients were followed for 26
- weeks from the date of their initial CDI diagnosis. Recurrence was defined as a CDI
- case occurring after an episode with positive assay result in the previous 2–8 weeks,
- 131 while incident infection was defined as a CDI case occurring after more than 8 weeks
- [5]. All-cause 30-day mortality was defined as death for any reason within 30 days of
- 133 CDI diagnosis. CDI severity was defined according to guidelines published by the
- European Society of Clinical Microbiology and Infectious Diseases [6]. A patient with
- any one of: white blood cell count > $15 \times 10^{9}$ /L, albumin level <30g/L, or serum creatinine
- 136 level  $\geq$ 133µM was considered to have severe CDI [6].

### 137 Statistical Analysis

- Logistic regression was used to determine prognostic factors for the composite outcome
- of recurrence or all-cause 30-day mortality for the overall cohort. Recurrence was
- selected as a patient-important outcome, as it is associated with a greater risk for
- 141 complications and adverse outcomes [2]. All-cause 30-day mortality was included in the

5

- composite outcome as it is a potential competing event for recurrence. All factors were
- determined a priori based on published guidelines [5–8]. Univariable analysis with P<0.2
- 144 was used, followed by stepwise selection in a multivariable logistic regression model.
- 145 The number of variables entered into the model enabled 80% study power with 15
- 146 events per factor.
- 147 To evaluate the impact of initial vancomycin treatment on adverse clinical outcomes in
- patients with first-episode non-severe CDI, the initial vancomycin versus initial
- 149 metronidazole cohorts were first examined in an unadjusted logistic regression analysis
- 150 for any combination of recurrence, incident infection, and all-cause 30-day mortality.
- 151 Prognostic factors for the overall cohort were then added to the adjusted multivariable
- 152 analysis.

# 153 **Results**

A total of 737 inpatients with first-episode CDI were included in our study. Their

- demographics, clinical data at the time of CDI diagnosis, initial CDI treatment, and
- outcomes are summarized in Table 1. Patients had a median age of 72.3 years (Q1:
- 157 61.2, Q3: 83.3) and 628 (85.2%) were classified to have non-severe CDI. 357 (48.4%)
- patients were classified to have hospital-acquired infection, while 309 (41.9%) and 71
- (9.6%) were classified to have acquired CDI in the community and other institutions,
- respectively. Most patients, 496 (67.3%), were initially diagnosed with CDI in a medical
- setting. At the time of CDI diagnosis, patients had an average temperature of 37.1°C
- (SD: 0.8) and a median white blood cell count of  $12.3 \times 10^9$ /L (Q1: 8.7, Q3: 18.1). The
- 163 median time to treatment following CDI diagnosis was 2 days (Q1: 1, Q3: 5). Most
- patients, 539 (73.1%), received initial metronidazole treatment, while 130 (17.6%)
- received initial vancomycin. Patients experienced a recurrence rate of 15.5%, an
- incident infection rate of 6.9%, and a 30-day mortality rate of 12.8%. The median time to
- recurrence was 29 days (Q1: 24, Q3: 36) and the median length of time spent in isolation was 17 days (Q1: 7, Q3: 34).

# 169 **Overall cohort**

- 170 The results of the multivariable logistic regression model to determine prognostic factors
- 171 for the composite outcome of recurrence or all-cause 30-day mortality for the overall
- cohort are summarized in Table 2. Predictors of the composite outcome were: age  $\geq 65$
- 173 years (OR<sub>adj</sub>: 2.01; 95% CI: 1.38–2.94; P<0.001), hospital-acquired infection (OR<sub>adj</sub>:
- 174 2.00; 95% CI: 1.44–2.80; P<0.001), and white blood cell count >15×10<sup>9</sup>/L (OR<sub>adj</sub>: 1.74;
- 175 95% CI: 1.24–2.44; P=0.001).
- Figure 1 illustrates the proportion of patients in the overall cohort who experienced recurrence or the composite outcome of recurrence or 30-day mortality, given the

6

- number of prognostic factors in the multivariable logistic regression model. At a score of
- 179 0 prognostic factors, the recurrence rate was 3.5% and the rate of recurrence or 30-day
- 180 mortality was 10.5%. At a score of 1, 2, or 3 prognostic factors, the recurrence rate
- increased to 15.6%, 17.6%, and 19.7%, respectively. Similarly, at 1, 2, or 3 prognostic
- 182 factors, the rate of the composite outcome of recurrence or 30-day mortality increased
- 183 to 22.6%, 32.1%, and 51.3%, respectively.

#### 184 Non-severe CDI cohort

- 185 There were 628 (85.2%) patients who were classified as having non-severe CDI, of
- 186 whom 499 (79.5%) and 129 (20.5%) were treated with initial metronidazole and initial
- vancomycin, respectively. Among patients with first-episode non-severe CDI,
- recurrence, incident infection, and 30-day mortality rates were 15.1%, 7.7%, and 13.1%,
- respectively, when treated with initial metronidazole, compared to 16.9%, 4.2%, and
- 190 11.4%, respectively, when treated with initial vancomycin. To evaluate the impact of
- initial vancomycin treatment for first-episode non-severe CDI, the initial vancomycin and
- initial metronidazole cohorts were first examined in a univariable logistic regression
- analysis, followed by an adjusted multivariable analysis. The use of initial vancomycin
- 194 for treatment of first-episode non-severe CDI was associated with a reduction in incident
- infection (OR<sub>adj</sub>: 0.18; 95% CI: 0.04–0.75; P=0.019) and the composite outcome of
- incident infection or 30-day mortality (OR<sub>adj</sub>: 0.42; 95% CI: 0.22–0.79; P=0.007),
- 197 compared to initial metronidazole (Tables 3-4).

# 198 **Discussion**

Although clinical trials have shown vancomycin to be superior to metronidazole for the 199 treatment of severe CDI [10], previous studies have suggested that metronidazole and 200 vancomycin are equally effective for the treatment of non-severe CDI [9-12]. Coupled 201 202 with the higher cost of vancomycin and concerns associated with vancomycin-resistant enterococci, metronidazole has been the drug of choice for the treatment of non-severe 203 CDI [14]. Given that some guidelines recommend the use of metronidazole for non-204 severe CDI [6-8], Figure 1 illustrates a scoring rule based on prognostic factors in Table 205 2 which could help identify low-risk patient populations who are likely to do well on initial 206 207 metronidazole. In recent years, however, guidelines, such as those published by the IDSA, have started to recommend initial vancomycin for the treatment of non-severe 208 CDI [5]. Our findings support this recommendation but are also consistent with the 209 conclusions of previous studies. The use of initial vancomycin for the treatment of non-210 211 severe CDI, for instance, was not associated with recurrence or 30-day mortality alone, which is consistent with previous findings [9–12]. A strength of our investigation was the 212 long duration of follow-up, 26 weeks in a pragmatic real-world setting, which allowed for 213 conclusions about the impact of initial vancomycin treatment on incident infection, 214

7

defined as a CDI episode occurring more than 8 weeks after the initial infection. In an adjusted analysis, the use of initial vancomycin for the treatment of first-episode nonsevere CDI was associated with a reduction in incident infection and the composite

severe CDI was associated with a reduction in incident infection
 outcome of incident infection or 30-day mortality.

The incidence of the virulent North American pulsed-field gel electrophoresis type 1

- (NAP1) strain has decreased over a 7-year period in Canadian hospital settings [15].
- Given that the NAP1 strain has been associated with higher mortality and a more
- complicated course of disease, compared to non-NAP1 strains [15], it is possible that a
- recent decline in NAP1 CDI cases could explain the reduction in the composite outcome
- of incident infection or 30-day mortality associated with the use of initial vancomycin for
- the treatment of first-episode non-severe CDI. At our institution, moreover, there has
- been an overall decline in incident infection rates in recent years, though it is unclear
- whether this should be attributed to the increased use of initial vancomycin treatment or
- other factors. A possible explanation for the lower incident infection rate experienced by
- 229 patients who received initial vancomycin could be the broader spectrum antimicrobial
- activity of metronidazole which may be more disruptive to gut flora and potentially
- predispose patients for reinfection and incident infection [2, 16, 17].

232 There were some limitations to our observational study. Patients were not randomized to treatment groups, for instance, and could have differed on key prognostic factors that 233 234 may have influenced patient outcomes. To mitigate differences between groups, an adjusted analysis was done using prognostic factors found for the overall cohort. 235 However, a limitation of our analysis was the exclusion of patient comorbidities in the 236 database. Another limitation was the possible misclassification of exposures, since the 237 treatment of CDI can evolve over a patient's stay. Patients were analyzed in a manner 238 239 analogous to the intention-to-treat approach, based on the initial treatment assignment, 240 and any treatment switches after 24 hours of the start of treatment were disregarded. Furthermore, although there was no observed increase in instances of vancomycin-241 resistant enterococci throughout our investigation, testing for this organism was non-242 243 systematic in nature. Finally, our investigation could have included some patients colonized with *Clostridioides difficile*, instead of true infection. This is unlikely, however, 244 as diagnosis of CDI was confirmed by one of three experienced infectious disease 245 physicians, all cases were followed by a dedicated CDI consultation team, and CDI 246 diagnosis required the presence of a positive toxin assay together with a clinical 247 248 presentation of 3 or more type 5–7 loose stools on the Bristol stool scale.

# 249 **Conclusions**

- 250 Initial vancomycin was associated with a reduction in incident infection and the
- composite outcome of incident infection or 30-day mortality in the treatment of adult

- 8
- inpatients with first-episode non-severe CDI, compared to initial metronidazole. These
- findings support the use of initial vancomycin for all inpatients with CDI, as
- recommended by IDSA guidelines [5].
- 255

### List of abbreviations

- 257 CDI: Clostridioides difficile infection
- 258 IDSA: Infectious Diseases Society of America
- 259 HAI: Hospital-acquired infection
- 260 NAP1: North American pulsed-field gel electrophoresis type 1
- 261

#### 262 **Declarations**

#### 263 Ethics approval and consent to participate

- This study was conducted in accordance with the Helsinki Declaration. The study
- protocol was approved by the Hamilton Integrated Research Ethics Board (Project:
- 266 2018-3543). The Hamilton Integrated Research Ethics Board has categorized this
- retrospective cohort study as minimal risk, defined as no potential for negative impact
- on the health and safety of the participant, and waiver of consent for participation wasobtained.
- 270 **Consent for publication**
- Not applicable.

#### 272 Availability of data and materials

- 273 The datasets generated for the study are not publicly available due to the presence of
- 274 personally identifiable information. Aggregate data, however, are presented in the
- 275 manuscript within the Tables and the Figure and are available from the corresponding
- author on reasonable request.

#### 277 Competing interests

- The authors declare that they have no competing interests.
- 279 Funding

280 The authors received no specific funding for this project.

## 281 Authors' contributions

- Kevin Zhang and Marek Smieja contributed to the conception and design of the work.
- Kevin Zhang, Patricia Beckett, Salaheddin Abouanaser, and Marek Smieja contributed
- to the acquisition of data, analysis, and interpretation of results. All of the authors
- drafted the manuscript, critically revised the paper, and approved the final manuscript.

## 286 Acknowledgements

Not applicable.

288			
289			
290			
291			
292			
293			
294			
295			
296			
297			
298			
299			
300			
301			

## 303 **References**

- 1. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al.
- Multistate Point-Prevalence Survey of Health Care–Associated Infections. N Engl J Med. 2014;370:1198–208. doi:10.1056/NEJMoa1306801.
- 2. Hopkins RJ, Wilson RB. Treatment of recurrent Clostridium difficile colitis: a narrative
   review. Gastroenterology Report. 2018;6:21–8. doi:10.1093/gastro/gox041.
- 309 3. Zhang K, Beckett P, Abouanaser S, Stankus V, Lee C, Smieja M. Prolonged oral
- vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection. BMC
   Infect Dis. 2019;19:51. doi:10.1186/s12879-019-3676-1.
- 4. Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al. Frozen vs
   Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients
- 314 With Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. JAMA.
- 315 2016;315:142. doi:10.1001/jama.2015.18098.
- 5. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al.
- 317 Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children:
- 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for
- Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases. 2018;66:e1–
- 320 **48. doi:10.1093/cid/cix1085.**
- 321 6. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and
- 322 Infectious Diseases: Update of the Treatment Guidance Document for Clostridium
- difficile Infection. Clinical Microbiology and Infection. 2014;20:1–26. doi:10.1111/1469-
- 324 **0691.12418**.
- 325 7. Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, et al.
- 326 2019 update of the WSES guidelines for management of Clostridioides (Clostridium)
- difficile infection in surgical patients. World J Emerg Surg. 2019;14:8.
- 328 doi:10.1186/s13017-019-0228-3.
- 8. Trubiano JA, Cheng AC, Korman TM, Roder C, Campbell A, May MLA, et al.
- Australasian Society of Infectious Diseases updated guidelines for the management of
- *Clostridium difficile* infection in adults and children in Australia and New Zealand: CDI management guidelines. Intern Med J. 2016;46:479–93. doi:10.1111/imj.13027.
- 332 management guidelines. Intern Wed J. 2016;46:479–93. doi:10.1111/IMJ.13027.
- 333 9. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A Comparison of Vancomycin
- and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea,
- 335 Stratified by Disease Severity. Clinical Infectious Diseases. 2007;45:302–7.
- doi:10.1086/519265.
- 10. Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, et al.
- 338 Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results

From Two Multinational, Randomized, Controlled Trials. Clinical Infectious Diseases.
 2014;59:345–54. doi:10.1093/cid/ciu313.

11. Stevens VW, Nelson RE, Schwab-Daugherty EM, Khader K, Jones MM, Brown KA,
 et al. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of
 Recurrence and Death in Patients With *Clostridium difficile* Infection. JAMA Intern Med.
 2017;177:546. doi:10.1001/jamainternmed.2016.9045.

12. Le F, Arora V, Shah DN, Salazar M, Palmer HR, Garey KW. A Real-World

346 Evaluation of Oral Vancomycin for Severe *Clostridium difficile* Infection: Implications for

- Antibiotic Stewardship Programs. Pharmacotherapy. 2012;32:129–34.
- 348 doi:10.1002/PHAR.1002.
- 13. Xia Y, Tunis M, Frenette C, Katz K, Amaratunga K, Rhodenizer Rose S, et al.
- Epidemiology of Clostridioides difficile infection in Canada: A six-year review to support
- vaccine decision-making. CCDR. 2019;45:191–211. doi:10.14745/ccdr.v45i78a04.
- 14. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance.
   Nat Rev Microbiol. 2012;10:266–78. doi:10.1038/nrmicro2761.
- 15. Katz KC, Golding GR, Choi KB, Pelude L, Amaratunga KR, Taljaard M, et al. The
   evolving epidemiology of *Clostridium difficile* infection in Canadian hospitals during a
   postepidemic period (2009–2015). CMAJ. 2018;190:E758–65.
- postepidemic period (2009–2015). CMAJ. 2
   doi:10.1503/cmaj.180013.
- 16. Rea MC, Dobson A, O'Sullivan O, Crispie F, Fouhy F, Cotter PD, et al. Effect of
   broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial
   diversity in a model of the distal colon. Proceedings of the National Academy of
- 361 Sciences. 2011;108 Supplement\_1:4639–44. doi:10.1073/pnas.1001224107.
- 17. Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK,
  Engstrand L. Short-Term Antibiotic Treatment Has Differing Long-Term Impacts on the
  Human Throat and Gut Microbiome. PLoS ONE. 2010;5:e9836.
- 365 doi:10.1371/journal.pone.0009836.
- 366

- 368
- 369
- 370
- 371
- 372

12

# 373 Figures, tables, additional files

374

**Table 1.** Description of patients with *Clostridioides difficile* infection (n = 737)

Demographics			
Age, median (Q1, Q3)	72.3 years (61.2, 83.3)		
Male	336 (45.6%)		
Hospital-acquired infection	357 (48.4%)		
Medical	496 (67.3%)		
Surgical	156 (21.2%)		
Nephrology	83 (11.3%)		
Non-severe Clostridioides difficile infection	628 (85.2%)		
Clinical Data			
Temperature, mean (SD)	37.1°C (SD: 0.8)		
Albumin, mean (SD)	23.1 g/L (SD: 6.2)		
Creatinine, median (Q1, Q3)	94.0 µmol/L (65.0, 185.8)		
White blood cell count, median (Q1, Q3)	12.3 × 10 <sup>9</sup> /L (8.7, 18.1)		
Initial Treatment Excluding Switches			
Metronidazole	539 (73.1%)		
Vancomycin	130 (17.6%)		
Metronidazole and vancomycin	62 (8.4%)		
Time to treatment, median (Q1, Q3)	2 days (1, 5)		
Outcomes			
Recurrence	114 (15.5%)		
Incident infection	51 (6.9%)		
30-day mortality	94 (12.8%)		
Time to recurrence, median (Q1, Q3)	29 days (24, 36)		
Isolation days, median (Q1, Q3)	17 days (7, 34)		

376

Sums may not add up to total due to missing data. Percentages exclude missing data.

377

378


379

- **Table 2.** Multivariable predictors of the composite outcome of recurrence or 30-day
- 382 mortality for patients in the overall cohort with *Clostridioides difficile* infection

Variable	Odds Ratio (95% CI)	Р
Age ≥65 years	2.01 (1.38 – 2.94)	<0.001
Hospital-acquired infection	2.00 (1.44 – 2.80)	<0.001
White blood cell count >15×10 <sup>9</sup> /L	1.74 (1.24 – 2.44)	0.001

383

384



- **Figure 1.** Proportion of patients in the overall cohort who experienced recurrence or the
- composite outcome of recurrence or 30-day mortality given the number of prognosticfactors
- 389 Legend
- 390 Recurrence or 30-day mortality
- 391 Recurrence
- 392

Table 3. Predictors of incident infection for patients with non-severe Clostridioides 

#### difficile infection

	Univariable		Multivariable	
Variable	Odds Ratio (95% CI)	Р	Odds Ratio (95% CI)	Р
Initial vancomycin	0.18 (0.04 – 0.76)	0.019	0.18 (0.04 – 0.75)	0.019
Age ≥65 years			0.63 (0.33 – 1.21)	0.169
Hospital-acquired infection			1.07 (0.57 – 2.01)	0.843
White blood cell count >15×10 <sup>9</sup> /L			0.86 (0.40 – 1.85)	0.702

- Table 4. Predictors of incident infection or 30-day mortality for patients with non-severe Clostridioides difficile infection

	Univariable		Multivariable		
Variable	Odds Ratio (95% CI)	Р	Odds Ratio (95% CI)	Р	
Initial vancomycin	0.43 (0.23 – 0.80)	0.008	0.42 (0.22 – 0.79)	0.007	
Age ≥65 years			1.16 (0.73 – 1.84)	0.524	
Hospital-acquired infection			1.31 (0.86 – 1.99)	0.208	
White blood cell count >15×10 <sup>9</sup> /L			1.40 (0.88 – 2.23)	0.155	